-
公开(公告)号:US11655252B2
公开(公告)日:2023-05-23
申请号:US17363494
申请日:2021-06-30
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Wenhua Jiao , Manjinder Singh Lall , Ricardo Lira , Mark Edward Schnute
IPC: C07D471/18 , A61K45/06
CPC classification number: C07D471/18 , A61K45/06 , C07B2200/13
Abstract: A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently hydrogen or hydroxy; wherein R1 and R2 are not both hydroxy. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.-
公开(公告)号:US10822341B2
公开(公告)日:2020-11-03
申请号:US16181596
申请日:2018-11-06
Applicant: Pfizer Inc.
Inventor: Matthew Frank Brown , Alpay Dermenci , Andrew Fensome , Brian Stephen Gerstenberger , Matthew Merrill Hayward , Dafydd Rhys Owen , Stephen Wayne Wright , Li Huang Xing , Xiaojing Yang
IPC: C07D487/04
Abstract: A compound compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A′ and A″ are independently O, C═O, C—R′ or N—R″, where R′ and R″ may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R″ may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A′ and A″ is O or C═O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C1-C6 alkyl; X is C—R3 or N, where R3 may be H or C1-C6 alkyl; R4 and R5 are independently H, amino, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R6, R7 and R8 are each independently H, C1-C6 alkyl, C1-C4 alkoxy(C1-C6 alkyl), or C3-C8 cycloalkyl, said C1-C6 alkyl is optionally substituted by halo, CN or hydroxy; or, R7 and R8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C1-C6 alkyl; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
-
公开(公告)号:US12129256B2
公开(公告)日:2024-10-29
申请号:US17939375
申请日:2022-09-07
Applicant: PFIZER INC.
Inventor: Matthew Frank Brown , Alpay Dermenci , Andrew Fensome , Brian Stephen Gerstenberger , Matthew Merrill Hayward , Dafydd Rhys Owen , Stephen Wayne Wright , Li Huang Xing , Xiaojing Yang
IPC: A61K31/4985 , C07D487/04
CPC classification number: C07D487/04 , A61K31/4985
Abstract: A compound having the structure:
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A′ and A″ are independently O, C═O, C—R′ or N—R″, where R′ and R″ may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R″ may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A′ and A″ is O or C═O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C1-C6 alkyl; X is C—R3 or N, where R3 may be H or C1-C6 alkyl; R4 and R5 are independently H, amino, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R6, R7 and R8 are each independently H, C1-C6 alkyl, C1-C4 alkoxy(C1-C6 alkyl), or C3-C8 cycloalkyl, said C1-C6 alkyl is optionally substituted by halo, CN or hydroxy; or, R7 and R8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C1-C6 alkyl; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.-
4.
公开(公告)号:US20240124439A1
公开(公告)日:2024-04-18
申请号:US18257195
申请日:2021-12-13
Applicant: Pfizer Inc.
Inventor: Scott William Bagley , Agustin Casimiro-Garcia , Jennifer Elizabeth Davoren , Rajiah Aldrin Denny , Brian Stephen Gerstenberger , Katherine Lin Lee , Frank Eldridge Lovering , Mihir Dineshkumar Parikh , Joseph Walter Strohbach , John Isidro Trujillo
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The invention relates to imidazopyridines of Formula (I)
and pharmaceutically acceptable salts thereof, wherein R0 to R5 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes.
The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.-
公开(公告)号:US11708360B2
公开(公告)日:2023-07-25
申请号:US17192968
申请日:2021-03-05
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Andrew Christopher Flick , Daniel Wei-Shung Kung , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, Jr. , Daniel Copley Schmitt , Mark Edward Schnute , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
CPC classification number: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/65583
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B)
or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.-
6.
公开(公告)号:US20240132477A1
公开(公告)日:2024-04-25
申请号:US18257136
申请日:2021-12-13
Applicant: PFIZER INC.
Inventor: Scott William Bagley , Agustin Casimiro Garcia , Jennifer Elizabeth Davoren , Rajiah Aldrin Denny , Brian Stephen Gerstenberger , Frank Eldridge Lovering , Mihir Dineshkumar Parikh , Joseph Walter Strohbach , John Isidro Trujillo
IPC: C07D403/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14
CPC classification number: C07D403/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14
Abstract: The invention relates to benzimidazoles of Formula (I)
and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes.
The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.-
公开(公告)号:US11661419B2
公开(公告)日:2023-05-30
申请号:US17126358
申请日:2020-12-18
Applicant: Pfizer Inc.
Inventor: Scott William Bagley , Agustin Casimiro-Garcia , Xiayun Cheng , Jennifer Elizabeth Davoren , Rajiah Aldrin Denny , Brian Stephen Gerstenberger , Frank Eldridge Lovering , Mihir Dineshkumar Parikh , Joseph Walter Strohbach , John Isidro Trujillo
IPC: C07D413/14 , A61P17/00 , A61K45/06
CPC classification number: C07D413/14 , A61K45/06 , A61P17/00
Abstract: The invention relates to benzimidazoles of Formula (I)
and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes.
The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.-
公开(公告)号:US11472809B2
公开(公告)日:2022-10-18
申请号:US17014533
申请日:2020-09-08
Applicant: Pfizer Inc.
Inventor: Matthew Frank Brown , Alpay Dermenci , Andrew Fensome , Brian Stephen Gerstenberger , Matthew Merrill Hayward , Dafydd Rhys Owen , Stephen Wayne Wright , Li Huang Xing , Xiaojing Yang
IPC: A61K31/4985 , C07D487/04
Abstract: There is a method for treating a psoriasis. A compound is administered in a therapeutically effective amount to a subject suffering therefrom. The compound has the structure or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
-
公开(公告)号:US11254668B2
公开(公告)日:2022-02-22
申请号:US16638271
申请日:2018-08-09
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Andrew Fensome , Dafydd Rhys Owen , Matthew Frank Brown , Matthew Merrill Hayward , Felix Vajdos , Li Huang Xing , Stephen Wayne Wright
IPC: C07D471/04 , C07D401/04 , C07D401/14 , C07D405/14 , C07D519/00
Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein variables are defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
-
公开(公告)号:US20240368144A1
公开(公告)日:2024-11-07
申请号:US18311266
申请日:2023-05-03
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Andrew Christopher Flick , Daniel Wei-Shung Kung , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, JR. , Daniel Copley Schmitt , Mark Edward Schnute , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
-
-
-
-
-
-
-
-
-